SummaryThis study has two phases. Phase 1 is a dose-finding study. Participants enrolled in this part of the study will receive escalating doses of SLN124 which will be administered as an injection under the skin.
Participants enrolled in Part 2 will be randomly allocated to receive either SLN124 or a placebo, both given via an injection under the skin.
Treatment TypeSystemic therapy (chemotherapy, hormone therapy or immunotherapy)
Use the hyperlinks, where available to access additional clinical trial information.
Silence Therapeutics plc
Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera